Research aims to optimize brain’s defense mechanisms to combat TBI

January 4, 2018

By Jan Jarvis

Phot of Victor Uteshev
 
A traumatic brain injury, or TBI, can happen to anyone at any age, in any place and under all manner of circumstances.

An estimated 1.7 million people in the United States experience loss of cognitive and sensorimotor functions following TBI annually. Those who survive the initial injury often cope with enormous losses in productivity, independence and quality of life.

Researchers at UNT Health Science Center, in collaboration with Epigen Biosciences Inc., a pharmaceutical company in San Diego, are exploring a family of novel compounds that could change how these injuries are treated. This Phase I study is funded by a $417,000 grant from the National Institutes of Health.

The path to clinically effective solutions for TBI is riddled with bumps and puddles, said Victor Uteshev, PhD, Associate Professor of Pharmacology & Neuroscience. TBI presents a considerable intellectual challenge because it is such a complex personal disorder. The concept of individualized medicine is highly relevant to TBI.

“Rephrasing Leo Tolstoy: Healthy brains are all alike, but every traumatically injured brain is unhealthy in its own way,” Dr. Uteshev said. “As a result, development of standardized treatments suitable for all or even many traumatically injured brains is a tremendous challenge. But solving scientific challenges is our job, not inconvenience.”

Despite multiple failures of other approaches in the treatment of TBI, Dr. Uteshev remains optimistic about his novel approach “because we have a powerful ally – nature. The human brain has an intrinsic ability to defend itself from injuries. The defense mechanisms that we study employ the Alpha-7 nicotinic receptors that are very common.”

A balanced activation of Alpha-7 receptors is beneficial for human health.  Whenever a brain injury occurs, two simultaneous processes are automatically initiated as the injury stimulates Alpha-7 receptors. First, the brain tissue near the site of injury becomes protected from spreading injury. Then the injury-induced inflammation is mitigated to prevent additional injury.

What Dr. Uteshev proposes is to optimize these two processes by a single class of drugs called positive allosteric modulators of Alpha-7 receptors.

“These drugs may help achieves a healthy balance by modulating natural activation of Alpha-7 receptors after TBI,” he said. “We believe that our novel approach may eventually allow clinicians to optimize the hardwired natural defense mechanisms that are already pre-installed.”

 

Jerry Simecka
Relieving the pain of peripheral arterial disease

By Jan Jarvis [caption id="attachment_200398685" align="alignright" width="200"] Dr. Jin Liu[/caption] For someone with peripheral arterial disease – a condition that causes narrowing of arteries in the limbs - pain is a big problem. “The treatment for it is exercise,” said Eric G...Read more

Jul 19, 2018

Heath Fc
Protecting her daughters’ generation from Alzheimer’s

By Alex Branch Janet Heath has a deeply personal interest in Alzheimer’s disease. Her mother suffered from it, as did her grandmother. Heath spent the last 10 years of her mother’s life trying to coordinate high-quality care as the disease took its terrible toll. That’s why Heath and ...Read more

Jul 17, 2018

Sid Fc
A blood test that IDs Alzheimer’s earlier, easier and cheaper

By Jan Jarvis   The first study of a blood test to detect Alzheimer’s disease within a primary care setting soon will be conducted at UNT Health Science Center. The simple test could be a game-changer in the diagnosis of early Alzheimer’s. If successful, it would be possible to ide...Read more

Jul 12, 2018

Dr. Taylor
New Provost: Let’s ‘unleash our strengths and ignite our future’

By Jeff Carlton Charles Taylor, PharmD, who has presided over a number of critical academic milestones as Dean of the UNT System College of Pharmacy, will become Provost and Executive Vice President of Academic Affairs at UNT Health Science Center. Dr. Taylor said he was “excited, honore...Read more

Jul 11, 2018